Edition:
United States

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

4.70USD
23 Apr 2018
Change (% chg)

$-0.07 (-1.47%)
Prev Close
$4.77
Open
$4.76
Day's High
$4.85
Day's Low
$4.67
Volume
122,626
Avg. Vol
286,205
52-wk High
$9.86
52-wk Low
$1.13

Chart for

About

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral... (more)

Overall

Beta: 2.70
Market Cap(Mil.): $193.28
Shares Outstanding(Mil.): 40.52
Dividend: --
Yield (%): --

Financials

  MRNS.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -0.82 -- --
ROI: -46.38 13.60 13.19
ROE: -47.55 15.26 15.00

BRIEF-Marinus Pharmaceuticals Provides Business Update And 2017 Financial Results

* MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND 2017 FINANCIAL RESULTS

Mar 06 2018

BRIEF-Marinus Pharmaceuticals files for mixed shelf of up to $200 mln

* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​ Source text: [http://bit.ly/2z23P1a] Further company coverage:

Oct 31 2017

BRIEF-Marinus Pharmaceuticals qtrly loss per share $0.15‍​

* Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results

Oct 31 2017

Earnings vs. Estimates